JP2018520669A - 腫瘍免疫療法 - Google Patents

腫瘍免疫療法 Download PDF

Info

Publication number
JP2018520669A
JP2018520669A JP2017565788A JP2017565788A JP2018520669A JP 2018520669 A JP2018520669 A JP 2018520669A JP 2017565788 A JP2017565788 A JP 2017565788A JP 2017565788 A JP2017565788 A JP 2017565788A JP 2018520669 A JP2018520669 A JP 2018520669A
Authority
JP
Japan
Prior art keywords
mirna
cells
promoter
nucleic acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017565788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520669A5 (https=
Inventor
ルー，ティモシー，クァン−タ
ニッシム，ライオール
ウー，ミン−ルー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2018520669A publication Critical patent/JP2018520669A/ja
Publication of JP2018520669A5 publication Critical patent/JP2018520669A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
JP2017565788A 2015-06-19 2016-06-17 腫瘍免疫療法 Pending JP2018520669A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562181906P 2015-06-19 2015-06-19
US62/181,906 2015-06-19
US201662325314P 2016-04-20 2016-04-20
US62/325,314 2016-04-20
PCT/US2016/038222 WO2016205737A2 (en) 2015-06-19 2016-06-17 Tumor immunotherapy

Publications (2)

Publication Number Publication Date
JP2018520669A true JP2018520669A (ja) 2018-08-02
JP2018520669A5 JP2018520669A5 (https=) 2019-07-18

Family

ID=57546436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565788A Pending JP2018520669A (ja) 2015-06-19 2016-06-17 腫瘍免疫療法

Country Status (7)

Country Link
US (1) US20190002912A1 (https=)
EP (1) EP3310915A4 (https=)
JP (1) JP2018520669A (https=)
CN (1) CN108350445A (https=)
AU (1) AU2016279050A1 (https=)
HK (1) HK1257177A1 (https=)
WO (1) WO2016205737A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
WO2018022747A1 (en) 2016-07-26 2018-02-01 Senti Biosciences, Inc. Genetic erasers
WO2018169901A1 (en) * 2017-03-13 2018-09-20 Massachusetts Institute Of Technology Synthetic promoters
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN112654711B (zh) * 2018-08-29 2024-03-26 上海科技大学 Cas蛋白抑制剂的组合物及应用
US12398428B2 (en) * 2019-02-06 2025-08-26 Cornell University DARC expression as prognosticator of immunotherapy outcomes
JP2023504884A (ja) * 2019-12-05 2023-02-07 ヴィセリックス・インコーポレーティッド ユニバーサル細胞療法のための免疫逃避機構のモジュレーター
CN116859048A (zh) * 2022-12-09 2023-10-10 上海交通大学医学院附属第九人民医院 肿瘤标志物跨膜蛋白slc31a1及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533847A (ja) * 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2008134593A1 (en) * 2007-04-25 2008-11-06 President And Fellows Of Harvard College Molecular circuits

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533847A (ja) * 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ コレステロール関連障害のａａｖベースの治療

Also Published As

Publication number Publication date
US20190002912A1 (en) 2019-01-03
WO2016205737A3 (en) 2017-02-02
AU2016279050A1 (en) 2018-01-04
EP3310915A2 (en) 2018-04-25
WO2016205737A2 (en) 2016-12-22
AU2016279050A2 (en) 2018-01-04
HK1257177A1 (zh) 2019-10-18
CN108350445A (zh) 2018-07-31
EP3310915A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
JP2018520669A (ja) 腫瘍免疫療法
Zuo et al. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
JP7710644B2 (ja) 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法
US10232053B2 (en) Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
RU2725799C2 (ru) Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними
KR102935974B1 (ko) 키메라 항원 수용체 및 이의 용도
CN110088285A (zh) 时空调节子
CA3097399A1 (en) T cell receptors with mage-b2 specificity and uses thereof
EP3768305B1 (en) Modified oncolytic adenoviruses
US20240309400A1 (en) Vectors
CN114761084A (zh) 具有铰链结构域的Notch受体
Brücher et al. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy
WO2018083259A1 (en) Oncolytic adenovirus encoding transgenes
US11672827B2 (en) Pharmaceutical chimeric receptor composition and method thereof
CN115948344A (zh) 嵌合抗原受体nk细胞、制备方法及其用途
CN113416260A (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
KR20210150446A (ko) 종양 항원 인식 수용체를 함유하는 면역 세포 및 이의 적용
CN111607006B (zh) 武装靶向cxcr2配体的特异性嵌合抗原受体细胞及其制备方法和应用
CN106467576B (zh) 一种抗体融合蛋白及其制备方法与应用
KR20230040364A (ko) 키메라 항원 수용체 및 이의 용도
CN115161293B (zh) 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用
Bhattacharyya et al. Lung Cancer Immunotherapy Approaches: From Clinical Testing to Future Advances
WO2025002479A1 (zh) 一种基于胞内区截短体的嵌合抗原受体
WO2024245291A1 (zh) 一种金属蛋白酶激活型car-t结构的制备及其应用
CN120035667A (zh) 用于免疫检查点抑制的多顺反子miRNA构建体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210126